A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients

Chinese Journal of Lung Cancer

Volumn 14, Issue 7, 2011, Pages 588-592

  Li, Zhixi ^a   Hou, Mei ^a   Wang, Haiyan ^a   wang, Zeyang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cisplatin; Gemcitabine; Lung neoplasms; Oxaliplatin; The elderly

Indexed keywords

CISPLATIN; GEMCITABINE; OXALIPLATIN;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPATHOLOGY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 79960600261     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.07.05     Document Type: Article

References (14)

1. Melotti B, Martoni AA. Gemcitabine (EM) (day 1-8) plus carboplatin (CBDCA) (days) for the treatment of advanced non-small cell lung cancer (aNSCLC) in elderly or poor performance status (PS) patients (pts). J Clin Oncol, 2007, 25(18): 18116.
2. Harpet P. Update on gemcitabine/carboplatin in patients with advanced non small cell lung cancer. Semin Oncol, 2003, 30(4 Suppl 10): 2-12.
3. Raymond E, Chaney SG, Taama A, et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol, 1998,9(10): 1053-1071.
4. Misset JL. Oxalitlatin in practice. Br J Cancer, 1998, 77(Suppl 4): 4-7.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Clin Oncol, 2000, 18(16): 2983-2947.
6. Faivre S, Le Chevalier T, Monnerat C, et al. Phase 1-2 and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small cell lung cancer and ovarian carcinoma. Ann Oncol, 2002, 13(9): 1479-14S9.
7. Franciosi V, Barbieri R, Aitini E, et al. Gemeitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung cancer, 2003, 41 (l): 101-106.
8. Grossi F, Aita M, Defferrari C, et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer. Oncologist, 2009, 14(5): 497-510.
9. Le Chevalier T. Chemotherapy for advanced NSCLC: Will meta-analysis provide the answer? Chest, 1996, 109(5 Suppl): 107S-109S.
10. Ibrahim A, Hirschfeld S, Cohen MH, et al. FDA drug approval summaries: oxaliplatin. Oncologist, 2004, 9(l): 8-12.
11. Armand JP, Sun Y, Guan ZZ, et al. Oxaliplatin in the treatment of advanced colorectal cancer. Ai Zheng, 1999, 18(6): 624-630.
12. Schmelz R, Lersch C. Acute oxaliplatin-induced peripheral-nerve hyperexcitability. J Clin Oncol, 2002, 20(16): 3561-3562.
13. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase 3 study in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 18_suppl (June 20 Supplement), 2010: 2.
14. Sun Q, Hua J, Hang XS, et al. Randomized clinical study comparing gemcitabine and oxaliplatin versus gemcitabine and cisplatin for advanced non-small cell lung cancer in elderly patients. Chin J Lung Cancer, 2005, 8(5): 451-453.